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Abstract
Cystatin C is believed to prevent tumor progression by inhibiting the activities of a family of lysosomal cysteine proteases.
However, little is known about the precise mechanism of cystatin C function in prostate cancer. In the present study, we
examined the expression of cystatin C and its association with matrix metalloproteinases 2 (MMP2) and androgen receptor
(AR) in a tissue microarray comparing benign and malignant specimens from 448 patients who underwent radical
prostatectomy for localized prostate cancer. Cystatin C expression was significantly lower in cancer specimens than in
benign tissues (p,0.001) and there was a statistically significant inverse correlation between expression of cystatin C and
MMP2 (rs
2=20.056, p=0.05). There was a clear trend that patients with decreased level of cystatin C had lower overall
survival. Targeted inhibition of cystatin C using specific siRNA resulted in an increased invasiveness of PC3 cells, whereas
induction of cystatin C overexpression greatly reduced invasion rate of PC3 in vitro. The effect of cystatin C on modulating
the PC3 cell invasion was provoked by Erk2 inhibitor that specifically inhibited MAPK/Erk2 activity. This suggests that
cystatin C may mediate tumor cell invasion by modulating the activity of MAPK/Erk cascades. Consistent with our
immunohistochemical findings that patients with low expression of cystatin C and high expression of androgen receptor
(AR) tend to have worse overall survival than patients with high expression of cystatin C and high AR expression, induced
overexpression of AR in PC3 cells expressing cystatin C siRNA greatly enhanced the invasiveness of PC3 cells. This suggests
that there may be a crosstalk between cystatin C and AR-mediated pathways. Our study uncovers a novel role for cystatin C
and its associated cellular pathways in prostate cancer invasion and metastasis.
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Introduction
Prostate cancer (PCa) remains the most common and second
most lethal tumor in males in the Western World [1]. Approxi-
mately one-third of treated patients will relapse and no curative
treatmentcurrentlyexistsformetastaticdisease[2].The progression
through hormone-dependent to castration resistant and metastatic
prostate cancer is poorly understood. The processes of invasion and
metastasis by tumor cells are dependent on their ability to degrade
surrounding proteins and other tissue components. The proteolytic
enzymes and proteases such as collagenase and cathepsins are
necessary for this purpose, and thus play crucial roles in multiple
steps of cancer growth and metastasis [3,4]. Among proteases, the
matrix metalloproteinases MMPs and lysosomal cathepsins B have
been attributed major roles in prostate cancer progression [5–9]
[10,11]. Recently, MMP2 was also linked to an invasive phenotype
of prostate cancer cells [12] and expression of MMP2 in malignant
prostatic epithelium was demonstrated to be an independent
predictor of prostate cancer disease-free survival [13].
Cystatin C is a secreted cysteine protease inhibitor that regulates
bone resorption, neutrophil chemotaxis, and tissue inflammation as
well as resistance to bacterial and viral infections. It also serves as a
potent inhibitor of cathepsin B and other human lysosomal cysteine
proteases [14]. Cystatin C is also known to be a better marker for
renal injury than creatinine [15,16]. By inactivating cathepsin
protease activity, cystatin C inhibits cancer cell invasion and
metastasis [17,18]. Abnormal serum levels of cystatin C or cathepsin
B/cystatin C complex have been suggested as diagnostics and
prognostic indicators for cancers of skin, colon and lung [19].
Cystatin C has been suggested to play an important role in
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recently, serum cystatin C has been proposed as useful marker of
increased osteoblastic activity associated to bisphosphonate treat-
ments in prostate cancer patients with bone metastasis [21].
However, the role of cystatin C in prostate cancer progression and
its associated cellular and molecular networks remain to be
investigated.
Recent studies have shown that during tumorigenesis and
metastasis, various proteolytic cascades consisting of enzymes such
as cysteine proteases and MMPs act in a synchronized manner and
aid in tumor growth, invasion into surrounding tissues [10].
Cathepsin B has been implicated in the degradation of the
extracellular matrix (ECM) either in secreted form in the
extracellular space or attached to the cell surface [10]. In
particular, MMP-2 and MMP-9 have been suggested to be
associated with prostate cancer metastasis, as high levels of these
proteins were measured in plasma and urine in patients with
metastatic disease [5,22,23]. MMP9 has also been studied
intensively and is though to play a major role in two important
aspects of tumor progression, angiogenesis and vasculogenesis [8].
The metastatic process involves the coordination of several
cellular and signal-transduction pathways that allow cancer cells to
proliferate, remodel their surrounding environment, invade to
distant site and form new tumors. MAPK signalling pathways play
an important role in inducing secretion of proteolytic enzymes that
degrade the basement membrane, enhancing cell migration and
maintaining tumor cell growth [7]. Increases in MAPK activity
have been observed in advanced PCa suggesting that a
constitutively active Ras pathway might be associated with
prostate cancer progression and metastasis [7,24]. Importantly,
MAPK activation is linked to development of androgen-indepen-
dent prostate cancer, now commonly termed castration-resistant
prostate cancer (CRPC) [25,26,27].
Androgen receptor (AR), a member of the superfamily of
ligand-activated nuclear receptors, plays a central role in the
pathogenesis of primary and metastatic prostate cancer [28,29].
AR gene amplification is found in one third of advanced prostate
cancers and is believed to contribute to progression and metastasis
of prostate cancer [30,31,32,33]. AR does not act independently in
the regulation of tumor growth but requires interaction with co-
regulators [34]. Mutations in the gene or message of the AR are
the reasons for the increased androgen sensitivity of those tumors.
Local autocrine production of dihydrotestosterone and testoster-
one in prostate cancer cells diminishes the castration effect [35].
The crosstalk between AR and other signaling pathways (e.g.
MAPK) as well as changes in AR co-regulators [34] accelerate the
ligand independent activation of AR. Thus, AR plays a vital role
in both clinically localized and advanced prostate cancers.
The present study aimed to evaluate the expression of cystatin C
and its clinical relevance in prostate cancer, and to elucidate a novel
rolefor cystatinC in prostate cancer invasion. CystatinC is associated
with the proteolytic cascade and MAPK/Erk pathway together with
AR may act in a synchronized manner to promote tumor growth and
invasion into surrounding tissues. Here, we established for the first
time a functional link between cystatin C and MAPK-Erk signalling
and AR-mediated pathways in prostate cancer cells.
Results
Tissue Expression of Cystatin C in Prostate Cancer Is
Associated with MMP2 as a Marker for Invasiveness and
Clinical Outcome
Decreased cystatin C mRNA expression has been reported in
several types of solid tumors including breast cancer, colon cancer
and renal carcinoma [36,37]. However, the specific role of cystatin
C protein expression in prostate cancer progression and its
association with clinical characteristics has not been reported. We
utilized a tissue-microarray (TMA) containing specimens from
benign prostatic tissue and malignant tumors from 448 patients
who underwent radical prostatectomy for localized prostate
cancer. Expression of cystatin C was examined by immunohisto-
chemistry. Virtually all benign specimens showed markedly high
cytoplasmic protein expression of cystatin C while the matched
prostate cancer tissues consistently displayed weaker or undetect-
able immunostaining (Figure 1A, B). The difference was
statistically significant (p,0.001), suggesting that cystatin C
protein expression is, in general, down-regulated in prostate
cancer compared to benign epithelium. We then subdivided tumor
samples into two groups based on Gleason grades of individual
core biopsies, Gleason grade 2 or 3 (Group 1) vs. Gleason grade 4
or 5 (Group 2) [38]. We found decreased expression of cystatin C
in 61% tumor samples from group 1 compared with 72% of the
samples in Group 2 (Figure 1A). Both MMP2 and MMP-9, in
particular, have been found to be associated with prostate cancer
metastasis [13,39]. Recently, cystatin C was identified as a novel
substrate for MMP2 in cell-based proteomic analysis, suggesting
that there is a direct functional link between MMP2 and cystatin C
[40]. We therefore explored a possible association between cystatin
C expression and the expression of MMP2 in the patient samples
by immunohistochemical analysis of our tissue microarray
construct (TMA). Interestingly, expression of cystatin C protein
was inversely associated with MMP2 in the 448 patient material
which was statistically significant (rs
2=20.056, p=0.05). We
further investigated whether cystatin C expression correlated with
clinical outcome in prostate cancer patients, and we divided
patients into two groups based on the level of cystatin C
expression: cystatin C high (intensity of staining 2 or 3) or cystatin
C low (intensity of staining less than 2) group. We found no
significant difference in clinical parameters including Gleason
score, T stage/Pathology stage, metastasis free time, pretreatment
PSA levels, Biochemical recurrence PSA levels, Biochemical free
time and positive surgical margins between cystatin C high and
cystatin C low group (Table 1). We then investigated whether
clinical outcome including overall-survival (OS) differed between
cystatin C high and cystatin C low patients. Patients in the cystatin
C high group at 100 months from diagnosis had an OS of
approximately 40% compared to 25% for patients in the cystatin
C low group (p=0.307) (Figure 1C). Although we did not
achieve statistically significance, there is a clear trend that patients
with low level of cystatin C expression had worse outcome
compared with those with higher levels. When we assessed
whether biochemical recurrence-free survival differed between the
groups, there was also no significant difference (p=0.401)
(Figure 1D).
Tissue Expression of Androgen Receptor Is Inversely
Associated with Cystatin C Expression
Amplification and mutations of AR gene are identified as
critical factors related to the poor prognosis of prostate cancer. We
wanted to investigate whether cystatin C expression in combina-
tion with AR may predict outcome of the disease. We evaluated
expression of cystatin C in a subset of our TMA samples
comprising 99 patients with the most advanced disease and had
high level of AR expression. We divided these 99 patients into two
groups: the cystatin C-low/AR-high group and cystatin C-high/
AR-high group (Figure 2). Patients with low cystatin C levels and
high AR expression had lower overall survival (40%, at 100
months) compared with patients with high cystatin C levels and
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did not achieve statistical significance (p=0.094). This indicates
that patients who had low cystatin C and high AR expression tend
to have worse outcome compared with patients with high cystatin
C and high AR expression.
Cystatin C Expression in Prostate Cancer Cell Lines
Because cystatin C was down-regulated in prostate cancer
tissues and associated with increased expression of MMP2 that is
known to contribute to tumor invasion and metastasis, we wanted
to investigate the role of cystatin C expression in prostate cancer
cell growth, survival and invasion. We examined cystatin C
expression in three prostate cancer cell lines including the
androgen-sensitive LNCaP cells and androgen-insensitive PC3
and DU-145 cells (Figure 3). Cystatin C protein concentrations in
the supernatants were measured by ELISA, after culturing the
cells in serum-free media for 24 and 48 hours, respectively.
Interestingly, LNCaP cells which are known to be non-invasive
produced high levels of cystatin C, while the invasive cell lines PC3
and DU-145 showed lower levels of cystatin C secretion
Figure 1. Immunohistochemical analysis of cystatin C expression in TMA with malignant and benign samples from patients with
localized prostate cancer. A). Immunohistochemical analysis of cystatin C expression in benign and PCa specimens. Sections representing benign,
tissue and tumors of Gleason grade 3 and grade 5 are shown. Representative pictures were obtained using a 40x objective. B). The graph of
quantitative analysis of immunohistochemical staining of Cystatin C (score 0-negative, 1- moderate, 2- strong, 3- very strong) shows the comparison
between 448 benign and cancer specimens (average staining of duplicates of each specimen). The paired Wilcoxon’s rank sum test analyses were
used to assess the comparison between the groups. The mean values of intensities of staining (horizontal lines) with error bars representing 95%
confidence intervals for the mean are shown. The boxes represent the distribution of the expression of cystatin C in the groups. C) Overall survival in
patients with high or low expression of cystatin C in prostate cancer samples. Kaplan-Meier survival analysis was performed. D) Survival curves of time
to relapse as evaluated as a biochemical recurrence measured as by raise of PSA [57] for the low (intensity score 0–1.5) and high (intensity score 2–3)
cystatin C expression.
doi:10.1371/journal.pone.0007953.g001
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C were chosen for subsequent functional studies to evaluate the
effects of forced overexpression and knockdown of cystatin C on
PC3 cell invasion.
Down-Regulation of Cystatin C Is Linked to Invasion of
PC3 Cells
Since PC3 cells are invasive, express moderate level of cystatin C
and have lack functional AR, thus can be an excellent model for
combined studies on cystatin C and AR function. PC3 cells were
transfected with cystatin C siRNA vector or control siRNA vector
for24 hours.Immunoblot analysisconfirmedthatcystatinCsiRNA
specifically blocked the protein expression of cystatin C in PC3 cells
(Figure 4A). To examine the effect of cystatin C knock down on
modulating the invasive activity of PC3 cells, in vitro invasive
activity assays were performed to assess the proportion of PC3 cells
expressing cystatin C siRNA or control siRNA that have invaded
through matrigel coated membranes. A significantly higher
proportion of PC3 cells, transiently transfected with cystatin C
siRNA, migrated through matrigel coated chambers compared to
that of PC3 cells transfected with control siRNA (Figure 4B–C).
Next, we assessed whether cystatin C knockdown might have effect
on proliferation of prostate cancer cells. PC3 cells transfected with
cystatin C siRNA or control siRNA were subjected to BrdU
incorporation assay. Cellular proliferation was assessed after
24 hours or 48 hours of transfection. No significant differences in
proliferation rates between PC3 cells transfected with siRNA to
cystatin C or control siRNA were observed (data not shown),
suggesting that inhibition of cystatin C had no effect on PC3 cell
proliferation. We also evaluate the effect of cystatin C on cell cycle
distribution. Flow cytometric analysis was performed in cells
transfected with cystatin C siRNA or control siRNA, we did not
observe that silencing of cystatin C had any significant influence
Table 1. Demographic and clinical data for PCa patients with high or low expression of cystatin C.
N=435, Mean values Low Cystatin C (staining under 2) (n=315) High Cystatin C (staining 2–3) (n=120) P values
Gleason score 6.2 6.3 0.139
Clinical T stage 1.56 1.64 0.169
Pathological T stage 2.48 2.56 0.135
Metastasis free time 2.32 2.75 0.806
Survival time (months) 268 264 0.479
Progression free time/survival 29.4/61.3 30.3/64.17 0.793
Pretreatment PSA 9.0 8.78 0.743
BCR PSA 0.695 0.463 0.266
BCR free time 30.22 32.38 0.507
Positive surgical margin 0.54 0.56 0.635
BCR: Biochemical Recurrence.
doi:10.1371/journal.pone.0007953.t001
Figure 2. Kaplan-Meier survival analysis in 99 patients with
advanced prostate cancer. Overall survival in a group of 99 patients
with the most advanced prostate cancer (Gleason grade 4–5) which
were characterized by high expression of AR and were separated to
different groups based on cystatin C levels (low- intensity score 0–1.5
and high- intensity score 2–3).
doi:10.1371/journal.pone.0007953.g002
Figure 3. Cystatin C is expressed in the media of prostatic cells
lines. ELISA assay of supernatants from three different prostate cancer
cells lines, which were plated 24 h or 48 h before experiment was
carried out. Data are shown as average of triplicates6SD for 3
experiments.
doi:10.1371/journal.pone.0007953.g003
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Next, we wanted to test whether inhibition of cystatin C may have
any effect on the survivals of PC3 cells in response to the treatment
with cytotoxic agent. PC3 cells transfected with siRNA to cystatin C
or control siRNA were treated with the cytotoxic agent campto-
thecinat10 ng/mlto induceapoptosis.Treatment ofPC3cellswith
camptothecin successfully induced cell death in PC3 cells. PC3 cells
transfected with siRNA against cystatin C, however, showed no
significant difference in camptothecin-induced apoptosis as com-
pared with PC3 cells transfected with control siRNA (data not
shown).
Because inhibition of cystatin C in PC3 cells had significant
effect on PC3 cell invasion, we therefore assessed whether
overexpression of cystatin C might have inhibitory effects on the
invasive behavior of PC3 cells. To induce overexpression of
cystatin C in PC3 cells, PC3 cells were transfected with a cystatin
C expression vector or with an empty expression vector. The
stable overexpression of cystatin C in PC3 cells was achieved after
antibiotic selection. Overexpression of cystatin C in PC3 cells was
confirmed by immunoblot analysis (Figure 5A). When we
investigated the effect of overexpression of cystatin C on PC3
cell invasion, we noted that a significantly lower proportion of PC3
cells overexpressing cystatin C migrated through Matrigel-coated
Boyden chambers compared with cells expressing control vector
(Figure 5B–C). Taken together, our current data suggests an
important role for cystatin C to inhibit prostate cancer cell
invasion.
The Role of Erk2 Pathway in Cystatin C Mediated Effects
on Invasion
Next, we wanted to investigate the cellular mechanisms and
pathways by which cystatin C exerts its effect on PC3 cell invasion.
MAPK signalling pathways and TGFb pathways have been shown
to have functional link with proteolytic enzymes including cathepsin
family of proteins to promote the degradation of the basement
membrane, enhances cell invasion and maintains tumor cell growth.
Smad 2/3 proteins are the downstream effectors of TGFb signaling
and the target of MAPK/ERK pathways as well, we therefore
wanted to investigate whether cystatin C may have a direct
functional link to these signalling pathways. We firstly examined
whether cystatin C may mediate the activities of MAPK and TGFb
pathways by regulating the expression and phosphorylation of
Smad2 and Erk1/2 in PC3 cells. We examined phosphorylation of
Smad2 and Erk1/2 in PC3 cells transfected with cystatin C siRNA
or control siRNA (Figure 6A). Immunoblot analysis revealed that
an increase in the level of phosphorylated Smad2 and Erk1/2 was
Figure 4. The effect of knockdown of cystatin C on the invasion of PC3 cells. A). Immunoblotting of cystatin C in PC3 cells after treatment
with control (siCtr) and cystatin C (siCys) siRNA. B–C) Invasion assay in matrigel- coated Boyden chambers of PC3 cells with knockdown of cystatin C.
Representative image of invading cells is shown in (B) and quantitative analysis of invasion by measuring absorbance after staining of invading cells
with Cell Stain Solution containing crystal violet supplied in the Transwell Invasion assay (Chemicon, Millipore, CA) (C) Data6SD are representative for
at least 3 experiments;* p,0.01 (Student T-test).
doi:10.1371/journal.pone.0007953.g004
Figure 5. Cystatin C decreases invasion of prostate cancer cells. A) Immunoblot of cystatin C in PC3 cells after stable transfection with
pcDNA3.1 and cystatin C-pcDNA3.1 plasmids. Stable clones were established after 2 weeks of selection on neomycin. B–C) Invasion assay of PC3 cells
with overexpression of control or cystatin C plasmids. Representative images of cells are shown in B and quantification (absorbance) of data +SD
from 3 independent experiments is shown in C. *p,0.05 (Student T-test).
doi:10.1371/journal.pone.0007953.g005
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that both Smad2 and Erk1/2 may be the downstream effectors
inhibited by cystatin C (Figure 6A).
To functionally examine the role of Smad2 activation in PC3
cells, we tested if targeted Smad2 knockdown had any effect on
tumor cell invasion. We designed siRNA to specifically target
Smad2. Inhibition of Smad2 phosphorylation via Smad2 siRNA
mediated knockdown was achieved in PC3 cells and was
confirmed by immunoblot (data not shown). In vitro invasive
activity assays revealed that the proportion of migrating and
invading PC3 cells were similar in PC3 cells transfected with
Smad2 siRNA and in PC3 cells transfected with control siRNA
(Figure 6B–C). We then performed simultaneously targeted
knockdown of Smad2 and cystatin C in PC3 cells. PC3 cells that
were co-transfected with cystatin C siRNA and Smad 2 siRNA or
control siRNA were further applied on the invasion chamber for
the invasion assay. There was no differences in the invasion rate
between PC3 cells co-expressing cystatin C siRNA and Smad 2
siRNA and PC3 cells co-expressing cystatin C siRNA and control
siRNA (Figure 6B–C), suggesting that inhibition of Smad2 had
no additional effects on modulating invasion of PC3 cells
expressing cystatin C siRNA and that Smad2 may be not involved
in cystatin C-mediated tumor cell invasion.
Because an increase in the level of phosphorylated Erk1/2 was
also observed in PC3 cells transfected with cystatin C siRNA in the
above experiments, we therefore further investigated if activation
of Erk1/2 mediated the inhibitory effect of cystatin C on PC3 cell
invasion. Treatment with a MEK inhibitor (PD98059), a general
inhibitor of MAPK pathways had no effect on the invasive
behaviour of PC3 cells expressing cystatin C siRNA or control
siRNA (data not shown). We decided to selectively inhibit the
activities of Erk 1 or Erk2.
Firstly, we inhibited Erk 1 expression via siRNA targeted
knockdown. Inhibition of Erk 1 had no effect on the invasion of
PC3 cells expressing cystatin C siRNA (data not shown),
suggesting that Erk1 may be not involved in cystatin C associated
tumor cell invasion. Next, we used selective inhibitor of Erk2
activity, which blocked phosphorylation of Elk-1, a downstream
target of Erk2, in PC3 cells expressing cystatin C siRNA
(Figure 6D). We observed that Erk 2 inhibitor significantly
inhibited the rate of invasiveness in cells expressing cystatin C
siRNA compared to cells expressing control siRNA (Figure
6E–F). The Erk2 inhibitor had no effect on cell proliferation in
PC3 cells under the same condition (data not shown). These results
suggest that Erk2 may be a downstream target of cystatin C. This
suggests that PC3 cells that have low cystatin C and high level of
Erk2 activity may become more invasive compared with cells with
normal level of cystatin C and Erk 2 activity. Further, cystatin C
may mediate tumor cell invasion through MAPK/Erk2 signalling
pathways.
Figure 6. The role of Erk1/2 and Smad2 in cystatin C regulated invasion of PC-3 cells. A). Immunoblot analysis of P-Smad2 in PC-3 cells
after silencing of Smad2. B–C). Invasion assay in PC-3 cells after silencing of Smad2 simultaneously with knockdown of cystatin C. The representative
pictures are shown in B and quantitative results of 3 independent experiments are presented in C.* p ,0.05 (Student T-test). D). Immunoblot with
antibody against phosphorylated (Ser383)-Elk1 and cystatin C in the lysates from PC3 cells transfected transiently with siRNA cystatin C and control
siRNA and co-treated with Erk2 inhibitor (25 mM). Note that Erk2 inhibitor blocks downstream phosphorylation of Elk1 a target of Erk2 in cells with
knockdown of cystatin C. Data are representative for 2 experiments. E–F). Invasion assay in PC-3 cells after concomitant silencing of cystatin C and
inhibition of Erk2 with selective inhibitor. The representative pictures are shown in D and quantitative results of 2 independent experiments are
presented in E.* p ,0.05, #p,0.01 (Student T-test).
doi:10.1371/journal.pone.0007953.g006
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AR is an important downstream target of MAPK/Erk
pathways, and inhibition of Erk1/2 activity will lead to a
decreased expression of AR in prostate cancer cells [41].
Overexpression of AR in PC3 cells has been shown to influence
cell invasion and growth in vitro [42]. Since we have established a
direct functional link between cystatin C and Erk2 activity, and we
have demonstrated that PCa patients with low cystatin C levels
and concomitant high levels of AR showed a tendency towards a
worse outcome as compared to patients with high cystatin C and
high AR levels, we therefore wanted to assess the cellular and
molecular association between cystatin C and AR. We employed
PC3 cells that lack the functional AR to investigate a cooperative
role between AR and cystatin C. PC3 cells were co-transfected
with AR expressing vector along with cystatin C siRNA vector
designated as ‘‘siCysC, AR’’ or with a control vector designated as
‘‘sictr, AR’’. In a similar fashion, PC3 cells were also co-transfected
with a CMV vector and cystatin C siRNA (designated as ‘‘siCysC,
CMV’’) or a CMV expressing vector and a control siRNA (‘‘sictr,
CMV’’). The transfected PC3 cells were then subjected for
invasion assay. Overexpression of AR with concomitant knock-
down of cystatin C resulted in a significant increase in the rate of
invasion of PC3 cells compared with the controls (Figure 7A–B).
Thus, these results suggest that PC3 cells that lack the cystatin C
but have high level of AR may be more invasive than the control
cells with normal level of cystatin C and AR.
Discussion
In the present study, we have shown that in vitro silencing of
cystatin C by specific siRNA increased cancer cell invasion in
cooperation with Erk2 and AR signalling. We unravelled novel
molecular mechanisms by which cystatin C affects tumor cell
invasion demonstrating that cystatin C expression was downreg-
ulated in primary prostate tumors compared with benign tissues in
448 patients. Using a TMA comprising benign and tumor samples
from 448 patients, we showed an inverse correlation between
cystatin C and MMP2 expression. Several studies have convinc-
ingly demonstrated that cystatin C is an important inhibitor of
cathepsin B and tumor cell invasion [43,44]. Cathepsin B
influences tumor microenvironment by degradation of extracellu-
lar matrix and by activation of other proteolytic enzymes such as
pro-urokinase-type plasminogen activator (pro-uPA) and matrix
metalloproteases (MMPs) so that tumor cells can actively invade
and metastasize[45]. Overexpression of cystatin C has been shown
to inhibit the invasive potential of human melanoma and
glioblastoma cell lines [36,43]. Our present finding from the
investigation of clinical materials indicates that there is a direct link
between cystatin C and extracellular matrix protein MMP2 in
prostate cancer. We have not investigated the role of cystatin C in
modulation of cathepsin B activities in prostate cancer cells,
however it is an open possibility considering the similar
correlations in other type of tumors. Proteome signatures that
are hallmarks of proteolysis revealed cleavage of many known
MMP-2 substrates in the cellular context. Proteomic evidence of
MMP-2 processing of novel substrates was found. Cystatin C
protein is one of the substrate that is cleaved by MMP-2 [40]. We
provide further evidence supporting a previously proposed role of
cystatin C to prevent tumorigenesis and cancer cell invasiveness,
possibly due to its ability to inhibit the activity of extracellular
matrix proteins [46,47].
Our functional analysis in PC-3 cells further demonstrated that
inhibition of cystatin C via siRNA-mediated knockdown resulted
in a significant increase in the rate of invasion of PC3 cells. This
observation is consistent with previous demonstration in primary
prostatic tumors where the most invasive tumors had very low or
undetectable cystatin C expression. Thus, cystatin C may be
functionally important for cells to maintain normal behaviour,
Figure 7. AR regulates the invasion in the absence of cystatin C. A–B). Invasion assay of PC3 cells transfected with control siRNA or against
cystatin C and coexpressing AR. The pictures from representative experiment are shown in A and the quantitative absorbances of invading cells
(*p,0.05, cystatin C siRNA versus siRNA control, #p,0.05 AR versus CMV, Student T-test) after stating with Cell Stain Solution supplied in the
Transwell Invasion assay (Chemicon, Millipore, CA) are shown in B. The data are representative for 3 independent experiments.
doi:10.1371/journal.pone.0007953.g007
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overexpressing cystatin C via transient transfection displayed less
invasive phenotypes.
The Erk-MAPK pathway is a common signaling mechanism for
multiple growth factors that are involved in metastatic spread and
drug-resistance [48]. By employing siRNA against cystatin C, we
showed that cystatin C was inversely associated with the invasive
behavior of PC3 cells, and that cystatin C was involved in the
regulation of Erk kinase activity. We revealed that the increased
invasion rate of PC3 cells caused by silencing of cystatin C, was
specifically blocked by inhibition of Erk2. Erk-MAPK pathway has
been shown to be a target for anticancer drugs [49] and Erk2 effects
are strongly interrelated with downstream target, Elk-1 [50,51]. We
observed a sustained cystatin C-dependent Erk activation in PC3
cells and it is unclear whether this is due to a convergence of AR and
growth factor signalling pathways. We speculate that cystatin C may
inhibit the protease-dependent release of growth factors or regulate
activity status of receptor or phosphatases to modulate Erk2 activity.
Here, we show that knockdown of Erk activity decreased the
invasion rate of prostate cancer cells, which is consistent with the
previous work in vitro and in vivo [52]. It has also been shown that
inhibition of Erk1/2 suppressed in vivo invasiveness of a human
squamous cell carcinoma cell line[53]. Moreover in pancreatic
cancer cells TGFb treatment caused an epithelial-mesenchymal
transition that was associated with a more invasive phenotype and
with the activation of ERK-signaling cascade[54]. In prostate
cancer, constitutive activation of MAPK was related to the
progression to androgen independence[55]. Our finding provides
evidence that cystatin C regulates Erk activity in PC3 cells and that
loss of cystatin C might lead to an uncontrolled increase in the
activity of MAPK/Erk signaling cascades, and thereby result in an
increase in invasion of PC3 cells.
Understanding multiple pathways that cooperatively contribute
to tumor progression is of utmost importance for development of
new therapeutic agents in prostate cancer. In the present study, we
explored whether cystatin C is related to AR in androgen-
independent tumor cell invasion and metastasis. Our findings
suggest that loss of cystatin C and overexpression of AR may be
two cooperative events in the progression of prostate cancer. This
hypothesis was supported by our results from TMA studies of
primary prostate cancer and benign prostatic tissue from 448
patients. We show that tumors with low levels of cystatin C and
high AR levels exhibited a worse clinical outcome compared with
patients with high levels of cystatin C and AR. Overexpression of
AR is one of the mechanisms utilized by castration resistant
prostate cancer cells, to overcome the growth inhibitory effects of
hormone depletion therapy or other chemotherapy [56]. Here we
show that decreased expression of cystatin C with concomitant
overexpression of AR leads to further enhancement of cell
invasion. It has been shown that inhibition of Erk1/2 activity in
prostate cancer cell resulted in the reduction of AR gene
expression [41]. Given that cystatin C mediates the activity
of MAPK/Erk1/2, cystatin C may also contribute to the
regulation of AR expression through MAPK/Erk1/2 signalling.
In conclusion, our studies provide, new insights into the
mechanisms of cystatin C actions in prostate cancer cells, and may
provide valuable information on cancer targets for therapeutic
interventions.
Materials and Methods
Tissue Specimens and Tissue Microarray
Benign and malignant tissue specimens from a consecutive
series of 448 patients undergoing radical prostatectomy for
localized prostate cancer at Malmo ¨ University Hospital, Sweden,
between 1988 and 2003 were mounted in 17 tissue microarray
blocks using a manual tissue arrayer (Beecher Inc, Wisconsin WI)
as previously described[39]. One section form each block was
stained with hematoxylin/eosin and examined by a National
Board licensed Pathologist for the presence of tumor, including
Gleason grading of each individual core. The study was approved
by the Ethic’s committee at Lund University (#LU 909/03) by
December 17, 2003 and the Helsinki Declaration of Human
Rights was strictly observed. Patients were informed retrospec-
tively by advertisement in the local newspaper that their tissue
samples were to be used for TMA studies. The TMA was
constructed years after prostatectomy. In this study, the correlation
between the expression of cystatin C and clinical parameters were
investigated. The clinical parameters of the patients include:
pretreatment of PSA level, Gleason score, clinical and pathological
T stage, surgical margin status. Biochemical recurrence, was
defined as a detectable level of PSA at .0.2 ng/ml as previously
described [57,58] and confirmed by a subsequent increasing value.
Overall, cancer-specific, and recurrence-free survivals were
assessed. Overall survival with follow up time ranging from 1 to
200 months were recorded.
Cell Culture and Treatment
Human prostate cancer cell lines, LNCaP, PC-3 and DU-145
were purchased from the American Type Culture Collection
(Manassas, VA, USA). Cells were grown in RPMI 1640 medium
(LNCaP and DU-145) and F12-HAM’s medium (PC-3) (PAA
Laboratories GmbH, Linz, Austria) supplemented with 10% fetal
calf serum (Sigma Chemical, St Louis, MO, USA), penicillin
(100 U/mL) and streptomycin (100 mg/mL) (PAA Laboratories,
Austria).
The Erk2 selective inhibitor, 3-(2-aminoethyl-5(4-ethoxyphe-
nyl)methylene)-2,4-thiazolidinedione, HCl) (Calbiochem, Gibbs-
town, NJ) as previously described [59] was dissolved in DMSO
and was used at concentration of 25 mM. Cells were pre-treated
for 10 minutes with inhibitor and seeded for invasion assay at
concentration of 2610
5 PC3 cells per well. The cell invasion was
tested after 20 hours as described below.
Transfections and siRNA Treatment
Cells were seeded at 40–50% confluence onto 6-well plates.
siRNAs against cystatin C and Smad2 and negative controls were
purchased from Ambion (Austin, TX). Five nM of siRNA was
used for each transfection with Lipofectamine 2000 in Opti-MEM
(Invitrogen, Carlsbad, CA). Cells were harvested and used for
subsequent assays after 24 hours.
Vector with AR cDNA was kindly provided by Dr. Steven Balk
(BIDMC, Harvard Medical School) and was previously described
[60]. Empty pcDNA3.1 control plasmid was purchased from
Invitrogen. Cells were transfected with Amaxa nuclofection Kit as
previously described [39] and the transfection efficiency was 40–
50% as measured with GFP control plasmid. In the co-transfection
studies with siRNA and plasmids, transfections were carried out
with nucleofection techniques as previously described[61].
Cystatin C cDNA was amplified from PC3 cells with the
following primers:
F: 59CTC G’AATTC c ctc tcg cct gcg ccc cac tcc; and R:
59GC’GGCCGC gg cacaggccag cccggtac and subcloned into
pcDNA3.1 vector between EcoRI and NotI restriction sites. The
subcloning was verified by sequencing and restriction sites analysis.
pcDNA3.1 control and cystatinC-pcDNA3.1 vectors were used to
establish the stable PC3 cell line. Cells were transfected with
Lipofectamine 200 as described above and selected on 200 mg/ml
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PC3 cells was verified by immunoblotting.
Immunoblotting
Cells were lysed in ice-cold lysis buffer (150 mM NaCl, 50 mM
Tris-HCl pH 7.5, 1% NP-40, 10 mM NaF, 1%SDS, 1 mM
EDTA pH 8.0, 10 mM phenylmethylsulfonyl fluoride (PMSF) and
the protease inhibitor cocktail Complete Mini (Roche, Basel,
Switzerland). Samples were centrifuged for 20 min, 140006ga t
4uC and clear supernatants were collected. 20 mg of each protein
samples were separated on 12% SDS-PAGE gel followed by
transfer to nitrocellulose membrane Hybond
TMECL
TM (Amer-
sham Pharmacia Biotech, Buckinghamshire, U.K.). The mem-
branes were probed with appropriate primary antibodies followed
by horseradish peroxidase (HRP)-conjugated secondary antibodies
(Amersham Life Science, Alesbury, U.K.) at the dilution 1:5000
and visualized using the Enhanced ChemiLuminescence detection
system (ECL Plus) and ECL films (Amersham Pharmacia Biotech).
Antibodies
The following antibodies were used: polyclonal rabbit antibod-
ies against cystatin C (code no. A0451) and non-immune rabbit
IgG (code no. X0936) were purchased from DAKO A/S
(Glostrup, Denmark); monoclonal mouse anti-MMP2 (Chemicon,
Millipore, CA), monoclonal anti-MMP2 (LabVision, NeoMAr-
kers, Clone VC2, CA), polyclonal rabbit anti-phopho-Erk1/2,
anti-phospho-Smad2 (Ser465/467), polyclonal anti-Erk1/2 (Cell
Signaling Technology, MA), monoclonal goat anti-beta actin,
mouse monoclonal anti-phospho-(Ser 383)-Elk1 (Santa Cruz
Biotechnology), biotinylated secondary antibodies, anti-rabbit
and anti-mouse IgGs were included in DAKO ChemMate kit
(code no. K5003, BioTek
TMSolutions, Winooski, VT). Anti-
mouse, anti-goat, anti-rabbit HRP conjugated were from Amer-
sham Life Science (Alesbury, U.K.). A polyclonal rabbit antiserum
raised against human cystatin C, purified from urine (code 8206)
[62] was used as capture antibody in ELISA.
Immunohistochemistry
Immunohistochemistry on tumor tissue microarrays as wells as
evaluation and scoring was performed as previously described[61].
The specimens were viewed with an Olympus BX51 microscope
at magnification of 406. Each core of TMA was scored for the
intensity of staining in the scale of 0–3 (0-negative, 1- moderate, 2-
strong, 3- very strong). Positive staining in at least 60% of tumor or
benign areas was considered to be significant to score to any of the
group. For evaluation of survival curves, all the samples were
divided to two groups: for the low (intensity score 0–1.5) and high
(intensity score 2–3) cystatin C expression.
Invasion Assay
The invasion of PC3 cells was measured by using the Transwell
chambers (Chemicon, Millipore, CA) according to the manufac-
turer’s protocol. Briefly, the cells were transfected with siRNA
and/or plasmids and after 24 hours were seeded onto the
membrane of the upper chamber of the transwell at a
concentration of 2610
5/ml in 500 ml of HAM’s F-12 medium.
The medium in the upper chamber was serum-free. The medium
at the lower chamber contained 10% Foetal Calf serum as a
source of chemoattractants. Cells that passed through the Matrigel
coated membrane were stained with Cell Stain Solution
containing crystal violet supplied in the Transwell Invasion assay
(Chemicon, Millipore, CA) and photographed after 20 hours of
incubation. Absorbance was measured at 562 nm by ELISA
reader after dissolving of stained cells in 10% acetic acid.
Cystatin C ELISA
Quantitation of cystatin C in the supernatants of prostate cancer
cell lines by a specific ELISA was performed as we have previously
described[63].
Statistical Analysis
T-student Test for assessing the significance of in vitro
experimentation; Wilcoxon’s rank sum test was used to assess
the differences in the expression of cystatin C between benign and
malignant specimens; Kaplan Meier survival analysis were
performed. The two-sided log-rank test was used to test association
between variables and clinical and biochemical recurrence, with
95% confidence intervals. Spearman rank correlation test was
used to evaluate possible pair-wise correlations between the
expression of cystatin C and MMP2. The Statistical Package for
the Social Sciences (SPSS) version 11.5 (SPSS Inc. Chicago, IL)
was used for the analysis. P-values,0.05 were considered as
statistically significant.
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